In line with this, novel TPH1 inhibitors that do not cross the blood brain barrier have been developed, revealing that inhibition of peripheral 5-HT synthesis is sufficient to protect against diet-induced obesity, reduce blood glucose levels, adiposity, and prevent diet-induced liver steatosis 199,275. Here, TPH1 is linked to fatty liver disease.